Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
30 01 2019
Historique:
received: 25 06 2018
accepted: 03 12 2018
entrez: 1 2 2019
pubmed: 1 2 2019
medline: 11 8 2020
Statut: epublish

Résumé

Chronic lymphocytic leukaemia is the most prevalent leukaemia in Western countries. It is an incurable disease characterized by a highly variable clinical course. Chronic lymphocytic leukaemia is an ideal model for studying clonal heterogeneity and dynamics during cancer progression, response to therapy and/or relapse because the disease usually develops over several years. Here we report an analysis by deep sequencing of sequential samples taken at different times from the affected organs of two patients with 12- and 7-year disease courses, respectively. One of the patients followed a linear pattern of clonal evolution, acquiring and selecting new mutations in response to salvage therapy and/or allogeneic transplantation, while the other suffered loss of cellular tumoral clones during progression and histological transformation.

Identifiants

pubmed: 30700761
doi: 10.1038/s41598-018-37389-7
pii: 10.1038/s41598-018-37389-7
pmc: PMC6353992
doi:

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

975

Références

Nucleic Acids Res. 2000 Jan 1;28(1):352-5
pubmed: 10592272
Br J Haematol. 2009 Jun;145(6):788-800
pubmed: 19388938
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
PLoS One. 2009 Nov 11;4(11):e7767
pubmed: 19907642
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Blood. 2011 Mar 24;117(12):3391-401
pubmed: 21266718
Nature. 2011 Jun 05;475(7354):101-5
pubmed: 21642962
J Exp Med. 2011 Jul 4;208(7):1389-401
pubmed: 21670202
Nat Rev Cancer. 2011 Jun 16;11(7):460
pubmed: 21677678
Nature. 2012 Jan 11;481(7382):506-10
pubmed: 22237025
Nature. 2012 Jan 18;481(7381):306-13
pubmed: 22258609
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Cancer Cell. 2012 Aug 14;22(2):180-93
pubmed: 22897849
Blood. 2012 Nov 15;120(20):4191-6
pubmed: 22915640
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Mol Cancer Res. 2013 Aug;11(8):815-27
pubmed: 23645565
Nat Methods. 2014 Apr;11(4):396-8
pubmed: 24633410
Cancer Discov. 2014 Sep;4(9):1088-101
pubmed: 24920063
Expert Rev Hematol. 2015 Feb;8(1):71-8
pubmed: 25345442
Blood. 2015 Jul 23;126(4):445-53
pubmed: 26065654
Curr Protoc Bioinformatics. 2015 Jun 19;50:11.13.1-20
pubmed: 26094690
Br J Haematol. 2016 Feb;172(3):371-383
pubmed: 26597680
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Clin Cancer Res. 2017 Feb 1;23(3):735-745
pubmed: 27503198
Leukemia. 2017 Jul;31(7):1547-1554
pubmed: 27890934
PLoS Med. 2016 Dec 13;13(12):e1002197
pubmed: 27959929
Nat Commun. 2016 Dec 16;7:13765
pubmed: 27982015
Nat Med. 2017 Mar;23(3):376-385
pubmed: 28165479
J Clin Oncol. 2017 Mar 20;35(9):984-993
pubmed: 28297623
Nat Med. 2017 Oct 06;23(10):1135-1145
pubmed: 28985206
Clin Cancer Res. 2018 May 1;24(9):2214-2224
pubmed: 29203589
Blood. 2018 Apr 19;131(16):1820-1832
pubmed: 29358183
Medicine (Baltimore). 2018 Jul;97(30):e11619
pubmed: 30045301

Auteurs

Julia González-Rincón (J)

Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Sagrario Gómez (S)

Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.

Nerea Martinez (N)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Pathology Department/Translational Hematopathology Group, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain.

Kevin Troulé (K)

Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Javier Perales-Patón (J)

Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Sophia Derdak (S)

CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.

Sergi Beltrán (S)

CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.

Belén Fernández-Cuevas (B)

Hematology Department, Hospital Universitario Puerta de Hierro-Majadahonda and Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.

Nuria Pérez-Sanz (N)

Hematology Department, Hospital Universitario Puerta de Hierro-Majadahonda and Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.

Sara Nova-Gurumeta (S)

Hematology Department, Hospital Universitario Puerta de Hierro-Majadahonda and Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.

Ivo Gut (I)

CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.

Fátima Al-Shahrour (F)

Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Miguel A Piris (MA)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Pathology Department, Hospital Fundación Jiménez Díaz, Madrid, Spain.

José A García-Marco (JA)

Hematology Department, Hospital Universitario Puerta de Hierro-Majadahonda and Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain. jagarciam@aehh.org.

Margarita Sánchez-Beato (M)

Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain. msbeato@idiphim.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH